Previous
Pause
Next
Skip to Navigation
↓
Congresses
Year
Year
Year
-Year
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Researcher
- Any -
dgomez
usuario_prueba
Almeida e Silva, Filomena Augusta
Amorín , Ricardo
Angás Pajas, Jorge
Arenal , Raúl
Baptista , Pedro Miguel
Bernechea Navarro, María
Bover Arbós, Pere
Calvo Lacosta, Jorge Hugo
Carstensen , Hans-Heinrich
Castro Barrigón, Alberto
Cazcarro Castellano, Ignacio
Cobarrubias Baglietto, Sebastián Felipe
DeMiguel , Daniel
Espina Cadena, Laura
Fernandez Antoran, David
Ferrio Díaz, Juan Pedro
Gil Hernández, Vanesa
Gracia Lostao, Ana Isabel
Gurauskis , Jonas
Hernández Ainsa, Silvia
Hernández Latas, José Antonio
Hurtado Guerrero, Ramón
Jiménez Schuhmacher, Alberto
Juarez-Perez , Emilio J.
Köhler , Ralf
Martínez-Padilla , Jesús
Millán Gasca, Javier
Montiel , Manuel
Muñoz Soro, José Félix
Olmo , Jose
Ordovás Vidal, Laura
Philippidis , George
Pozo Gonzalo, Cristina
Ramón García, Santiago
Roque , Carla
Schoorlemmer , Jon
Sola , Daniel
Stavridis , Stelios
Sánchez Martínez, Diego
Velasco Lozano, Susana
Íñiguez Dieste, David
Title
Title
Year
ESTUDIOS DE ELUCIDACIÓN DEL MODO DE ACCIÓN DE LAS AVERMECTINAS FRENTE A MYCOBACTERIUM
2019
Estudios iniciales para la caracterización del modo de acción molecular de las avermectinas como agentes anti-tuberculosos
2018
Expert Campus | Focus on tuberculosis
2020
Expert campus | Focus on tuberculosis
2020
Fighting Mycobacterium abscessus infection in Cystic Fibrosis patients
2020
Hollow fiber system for TB: optimization studies with Moxifloxacin
2022
Hollow fiber system for tuberculosis setting up at university of Zaragoza
2022
Implementing best practises on data generation and reporting of Mycobacterium tuberculosis time kill assays: a case study of standardized protocol within the ERA4TB consortium
2022
In vitro killing dynamics of the diarylquinolone TBAJ-587 and its main metabolites against Mycobacterium tuberculosis
2022
In vitro profiling of anthelmintic avermectins against non-tuberculous mycobacteria
2019
In vitro synergy screens of FDA-approved drugs combined with last-line antibiotics reveal new bactericidal combinations against Klebsiella pneumoniae
2022
In vitro time-kill assays of amoxicillin/clavulanate in combination with rifampicin/clarithromycin against Mycobacterium ulcerans
2022
Innovative drug discovery and development strategies for antibacterial therapy: a focus on neglected diseases
2017
Mathematical model of meropenem against Mycobacterium tuberculosis
2019
Mode of action elucidation studies of a new chemical series active against Mycobacteria and other microbial pathogens
2019
Mode of action elucidation studies of the avermectins against Mycobacteria
2019
Multicentric in-vitro characterization of MPL-204, a new anti- tuberculosis drug candidate, by the ERA4TB collaborative initiative
2022
New methodologies to test antibiotic susceptibility against emerging pathogens in cystic fibrosis
2019
Novel in vitro synergistic combinations in the treatment of non-tuberculous mycobacteria
2021
Nuevos métodos para la búsqueda de combinaciones sinérgicas
2019
Pages
« primera
‹ anterior
1
2
3
4
siguiente ›
última »